The study exclusion criteria included: (i) patients with primary locally advanced NPC, (ii) pre-clinical studies, and (iii) studies not reporting molecular targeted therapies against VEGF and EGFR. This evidence concerns the gene EGFR and nasopharyngeal carcinoma.